These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 14705201)

  • 1. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph.
    Rodríguez-Hornedo N; Murphy D
    J Pharm Sci; 2004 Feb; 93(2):449-60. PubMed ID: 14705201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder.
    Murphy D; Rodríguez-Cintrón F; Langevin B; Kelly RC; Rodríguez-Hornedo N
    Int J Pharm; 2002 Oct; 246(1-2):121-34. PubMed ID: 12270615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a universal dissolution medium for carbamazepine.
    El-Massik MA; Abdallah OY; Galal S; Daabis NA
    Drug Dev Ind Pharm; 2006 Aug; 32(7):893-905. PubMed ID: 16908426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solvent-mediated solid phase transformations of carbamazepine: Effects of simulated intestinal fluid and fasted state simulated intestinal fluid.
    Lehto P; Aaltonen J; Tenho M; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
    J Pharm Sci; 2009 Mar; 98(3):985-96. PubMed ID: 18661533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate.
    Crison JR; Weiner ND; Amidon GL
    J Pharm Sci; 1997 Mar; 86(3):384-8. PubMed ID: 9050810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of intrinsic dissolution behavior of different carbamazepine samples.
    Sehić S; Betz G; Hadzidedić S; El-Arini SK; Leuenberger H
    Int J Pharm; 2010 Feb; 386(1-2):77-90. PubMed ID: 19900519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystallization of carbamazepine pseudopolymorphs from nonionic microemulsions.
    Kogan A; Popov I; Uvarov V; Cohen S; Aserin A; Garti N
    Langmuir; 2008 Feb; 24(3):722-33. PubMed ID: 18163657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Simulated Gastrointestinal Fluids on Polymorphic Behavior of Anhydrous Carbamazepine Form III and Biopharmaceutical Relevance.
    Bhise SB; Rajkumar M
    PDA J Pharm Sci Technol; 2010; 64(1):28-36. PubMed ID: 21502001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of egg albumin on the crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets and in aqueous solutions.
    Katzhendler I; Azoury R; Friedman M
    J Control Release; 2000 Apr; 65(3):331-43. PubMed ID: 10699292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To evaluate the effect of addition of an anionic surfactant on solid dispersion using model drug indomethacin.
    Dave RH; Patel AD; Donahue E; Patel HH
    Drug Dev Ind Pharm; 2012 Aug; 38(8):930-9. PubMed ID: 22085470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial dissolution kinetics of cocrystal of carbamazepine with nicotinamide.
    Hattori Y; Sato M; Otsuka M
    J Pharm Pharmacol; 2015 Nov; 67(11):1512-8. PubMed ID: 26285918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
    Miller JM; Beig A; Krieg BJ; Carr RA; Borchardt TB; Amidon GE; Amidon GL; Dahan A
    Mol Pharm; 2011 Oct; 8(5):1848-56. PubMed ID: 21800883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualizing the conversion of carbamazepine in aqueous suspension with and without the presence of excipients: a single crystal study using SEM and Raman microscopy.
    Tian F; Sandler N; Gordon KC; McGoverin CM; Reay A; Strachan CJ; Saville DJ; Rades T
    Eur J Pharm Biopharm; 2006 Nov; 64(3):326-35. PubMed ID: 16846721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media.
    Omori M; Watanabe T; Uekusa T; Oki J; Inoue D; Sugano K
    Mol Pharm; 2020 Oct; 17(10):3825-3836. PubMed ID: 32870691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.
    Yamashita H; Sun CC
    Pharm Res; 2017 Dec; 35(1):4. PubMed ID: 29288433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ monitoring of carbamazepine-nicotinamide cocrystal intrinsic dissolution behaviour.
    Qiao N; Wang K; Schlindwein W; Davies A; Li M
    Eur J Pharm Biopharm; 2013 Apr; 83(3):415-26. PubMed ID: 23159709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanistic study of griseofulvin dissolution into surfactant solutions under laminar flow conditions.
    Rao VM; Lin M; Larive CK; Southard MZ
    J Pharm Sci; 1997 Oct; 86(10):1132-7. PubMed ID: 9344170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Polymer/Surfactant as Carriers on the Solubility and Dissolution of Fenofibrate Solid Dispersion.
    Yang B; Wu L; Ke J; Zhou L; Chen M; Li S; Feng X
    AAPS PharmSciTech; 2019 Feb; 20(3):102. PubMed ID: 30723877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin.
    Rahman Z; Samy R; Sayeed VA; Khan MA
    Pharm Dev Technol; 2012; 17(4):457-65. PubMed ID: 21265708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs.
    Lehto P; Kortejärvi H; Liimatainen A; Ojala K; Kangas H; Hirvonen J; Tanninen VP; Peltonen L
    Eur J Pharm Biopharm; 2011 Aug; 78(3):531-8. PubMed ID: 21329757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.